NCT04355481

Brief Summary

The objective of this protocol is to estimate the proportion of patients hospitalized in intensive care unit for a SARS-Cov-2 viral lung infection and contaminating their environment at 1 meter. The contamination will be assessed by quantifying the viral RNA by RT-PCR on a 600-liter air sample aspirated by a Coriolis® system. This sample will be taken within 48 hours after the confirmation of SARS-Cov-2 infection, documented by RT-PCR. In fact, the hospital hygiene measures practiced in intensive care unit in patients with viral respiratory infection are identical to those practiced in other services. These measures are possibly insufficient as evidenced by recent data related to the COVID-19 epidemic.

Trial Health

43
At Risk

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Enrollment
150

participants targeted

Target at P50-P75 for all trials

Timeline
Completed

Started Apr 2020

Shorter than P25 for all trials

Geographic Reach
1 country

3 active sites

Status
unknown

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

April 17, 2020

Completed
Same day until next milestone

Study Start

First participant enrolled

April 17, 2020

Completed
4 days until next milestone

First Posted

Study publicly available on registry

April 21, 2020

Completed
6 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

October 17, 2020

Completed
2 months until next milestone

Study Completion

Last participant's last visit for all outcomes

December 17, 2020

Completed
Last Updated

April 24, 2020

Status Verified

April 1, 2020

Enrollment Period

6 months

First QC Date

April 17, 2020

Last Update Submit

April 21, 2020

Conditions

Keywords

SARS-Cov-2environmental contaminationintensive care unit

Outcome Measures

Primary Outcomes (1)

  • Estimate the proportion of patients hospitalized in intensive care for a SARS-Cov-2 viral lung infection and contaminating their environment at 1 meter.

    The primary objective of the study will be evaluated by the proportion of patients contaminating the air 1 meter from their face. The contamination will be assessed by quantifying the viral RNA by RT-PCR on a 600-liter air sample aspirated by a Coriolis® system. This sample will be taken within 48 hours after the confirmation of SARS-Cov-2 infection, documented by RT-PCR.

    within 48 hours of the confirmation of SARS-Cov-2 infection documented by RT-PCR

Eligibility Criteria

Age18 Years+
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)
Sampling MethodNon-Probability Sample
Study Population

Patients are recruited at the intensive care unit, for all patients admitted to intensive care for a low respiratory infection during which the SARS-Cov-2 virus (RT-PCR positive) is documented within 48 hours before carrying out the air and surfaces specimens.

You may qualify if:

  • Patient over 18 years old.
  • Patient admitted to intensive care unit for a low respiratory infection during which the SARS-Cov-2 virus is documented, with a positive RT-PCR in the 48 hours before taking samples.
  • Information and not opposition from the patient / or family

You may not qualify if:

  • No documentation of SARS-Cov-2 viral respiratory infection.
  • Patient under guardianship / curatorship

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (3)

Service de réanimation Hôpital Avicenne

Bobigny, 93000, France

RECRUITING

Service de réanimation Hôpital Bichat

Paris, 75018, France

NOT YET RECRUITING

Service de réanimation Hôpital Tenon

Paris, 75020, France

NOT YET RECRUITING

MeSH Terms

Conditions

COVID-19Virus Diseases

Condition Hierarchy (Ancestors)

Pneumonia, ViralPneumoniaRespiratory Tract InfectionsInfectionsCoronavirus InfectionsCoronaviridae InfectionsNidovirales InfectionsRNA Virus InfectionsLung DiseasesRespiratory Tract Diseases

Study Officials

  • Yacine TANDJAOUI-LAMBIOTTE, Dr

    Assistance Publique - Hôpitaux de Paris

    PRINCIPAL INVESTIGATOR

Central Study Contacts

Yacine TANDJAOUI-LAMBIOTTE, Dr

CONTACT

Study Design

Study Type
observational
Observational Model
COHORT
Time Perspective
PROSPECTIVE
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

April 17, 2020

First Posted

April 21, 2020

Study Start

April 17, 2020

Primary Completion

October 17, 2020

Study Completion

December 17, 2020

Last Updated

April 24, 2020

Record last verified: 2020-04

Locations